Effects of chloroquine on viral infections: An old drug against today's diseases?

Lancet Infectious Diseases

Volumn 3, Issue 11, 2003, Pages 722-727

  Savarino, Andrea ^a   Boelaert, Johan R ^b   Cassone, Antonio ^c   Majori, Giancarlo ^c   Cauda, Roberto ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b AZ Sint Jan   (Belgium)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

8 AMINOQUINOLINE DERIVATIVE; ANTIRETROVIRUS AGENT; CHLOROQUINE; DIDANOSINE; HYDROXYCHLOROQUINE; HYDROXYUREA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIMALARIAL ACTIVITY; ANTIVIRAL ACTIVITY; BIOCHEMISTRY; CLINICAL TRIAL; CORONAVIRUS; CYTOKINE PRODUCTION; DRUG EFFECT; FLAVIVIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; NONHUMAN; PH; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETROVIRUS; REVIEW; RISK BENEFIT ANALYSIS; SEVERE ACUTE RESPIRATORY SYNDROME; SIDE EFFECT; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0242355070     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(03)00806-5     Document Type: Note

References (61)

1. Canadian rheumatology association. Canadian Consensus Conference on hydroxychloroquine. J Rheumatol 2000; 27: 2919-21.
2. Savarino A, Gennero L, Sperber K, Boelaert JR. The anti-HIV-1 activity of chloroquine. J Clin Virol 2001; 20: 131-35.
3. Boelaert JR, Piette J, Sperber K. The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol 2001; 20: 137-40.
4. Ohkuma S, Poole B. Cytoplasmic vacuolation of mouse peritoneal macrophages and the uptake into lysosomes of weakly basic substances. J Cell Biol 1981; 90: 656-64.
5. Pescarmona GP, Morra E, Aldieri E, Ghigo D, Bosia A. Movements of vesicles in eukaryotic cells: role of intravesicle protons as a fuel and modulation of their concentration by drugs or metabolic changes. MRS Bull 1998; 489: 212-17.
6. Vezmar M, Georges E. Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs. Biochem Pharmacol 2000; 59: 1245-52.
7. Vezmar M, Georges E. Direct binding of chloroquine to the multidrug resistance protein (MRP): possible role for MRP in chloroquine drug transport and resistance in tumor cells. Biochem Pharmacol 1998; 56: 733-42.
8. Byrd TF, Horwitz MA. Chloroquine inhibits the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. A potential new mechanism for the therapeutic effect of chloroquine against intracellular pathogens. J Clin Invest 1991; 88: 351-57.
9. Legssyer R, Josse C, Piette J, Ward RJ, Crichton RR. Changes in function of iron-loaded alveolar macrophages after in vivo administration of desferrioxamine and/or chloroquine. J Inorg Biochem 2003; 94: 36-42.
10. Gonzalez-Dunia D, Cubitt B, de la Torre JC. Mechanism of Borna disease virus entry into cells. J Virol 1998; 72: 783-88.
11. Ros C, Burckhardt CJ, Kempf C. Cytoplasmic trafficking of minute virus of mice: low-pH requirement, routing to late endosomes, and proteasome interaction. J Virol 2002; 76: 12634-45.
12. Diaz-Griffero F, Hoschander SA, Brojatsch J. Endocytosis is a critical step in entry of subgroup B avian leukosis viruses. J Virol 2000; 76: 12866-76.
13. Bishop NE. Examination of potential inhibitors of hepatitis A virus uncoating. Intervirology 1998; 41: 261-71.
14. Ferreira DF, Santo MP, Rebello MA, Rebello MC. Weak bases affect late stages of Mayaro virus replication cycle in vertebrate cells. J Med Microbiol 2000; 49: 313-18.
15. Harley CA, Dasgupta A, Wilson DW. Characterization of herpes simplex virus-containing organelles by subcellular fractionation: role for organelle acidification in assembly of infectious particles. J Virol 2001; 75: 1236-51.
16. Randolph VB, Winkler G, Stollar V. Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology 1990; 174: 450-58.
17. Tsai WP, Nara PL, Kung HF, and Oroszlan S: Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses 1990; 6: 481-89.
18. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003; 361: 1111-18.
19. Jeong J-Y, Jue D-M. Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Immunol 1997; 158: 4901-07.
20. Bondeson J, Sundler R. Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin1β and tumor necrosis factor α in macrophages. General Pharmacol 1998; 30: 357-66.
21. Van den Borne BE, Dijkmans BA, de Rooij HH, le Cessie S, Verweij CL. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-α interleukin 6 and interferon-γ production by peripheral blood mononuclear cells. J Rheumatol 1997; 24: 55-60.
22. Karres I, Kremer J-P, Dietl I, Steckholzer U, Jochum M, Ertel W. Chloroquine inhibits proinflammatory cytokine release into human whole blood. Am J Physiol 1998; 274: R1059-64.
23. Picot S, Peyron F, Donadille A, Vuillez J-P, Barbe G, Ambroise-Thomas P. Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism. Immunology 1993; 80: 127-33.
24. Weber SM, Levitz SM. Chloroquine interferes with lipopolysaccharide-induced TNF-α gene expression by a nonlysosomotropic mechanism. J Immunol 2000; 165: 1534-40.
25. Jeong J-Y, Choi JW, Jeon K-I, Jue D-M. Chloroquine decreases cell-surface expression of tumour necrosis factor receptors in human histiocytic U-937 cells. Immunol 2002; 105: 83-91.
26. Nooteboom A, Hendriks T, Otteholler I, van der Linden CJ. Permeability characteristics of human endothelial monolayers seeded on different extracellular matrix proteins. Mediators Inflamm 2000; 9; 235-41.
27. Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol 1991; 23: 292-96.
28. Bernstein HN. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med 1983; 75: 25-34.
29. Herman K, Leys A, Spileers W. (Hydroxy)-chloroquine retinal toxicity: two case reports and safety guidelines. Bull Soc Beige Ophtalmol 2002; 284: 21-29.
30. Klinger G, Morad Y, Westall CA, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 2001; 358: 813-14.
31. Sperber K, Kalb TH, Stecher VJ, Banerjee R, and Mayer L. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retroviruses 1993; 9: 91-98.
32. Pardridge WM, Yang J, Diagne A. Chloroquine inhibits HIV-1 replication in human peripheral blood lymphocytes. Immunol Lett 1998; 64: 45-47.
33. Savarino A, Gennero L, Chen HC, et al. Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS 2001; 15: 2221-29.
34. Sperber K, Louie M, Kraus T, et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther 1995; 17: 622-36.
35. Sperber K, Chiang G, Chen H, et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with HIV-1. Clin Ther 1997; 19: 913-23.
36. Debiaggi M, Bruno R, Sacchi P, Filice G. Antiviral activity of chloroquine against HIV-1 strains resistant to antiretroviral drugs. Antiviral Res (in press).
37. Chiang G, Sassaroli M, Louie M, Chen H, Stecher VJ, and Sperber K. Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. Clin Ther 1996; 18: 1080-92.
38. Boelaert JR and Sperber K: Antiretroviral therapy. Lancet 1998; 352: 1224-25.
39. Boelaert JR, Sperber K, Piette J. Chloroquine exerts an additive in vitro anti-HIV-1 effect, when combined to zidovudine and hydroxyurea. Biochem Pharmacol 2001; 61: 1531-35.
40. Paton NI, Aboulhab J, Karim F. Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1. Lancet 2002; 359: 1667-68.
41. Boelaert JR, Dom GM, Huitema AD, Beijnen JH, Lange JM. The boosting of didanosine by allopurinol permits a halving of the didanosine dosage. AIDS 2002; 16: 2221-23.
42. Mofenson LM, McIntyre JA. Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet 2000; 355: 2237-44.
43. Boelaert JR, Yaro S, Augustijns P, et al. Chloroquine accumulates in breast milk cells. Potential impact as adjuvant to antiretroviral prophylaxis for postnatal mother-to-child transmission of HIV-1. AIDS 2001; 15: 2205-06.
44. DeCock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child transmission of HIV-1 in resource-poor countries: translating research into policy and practice. JAMA 2000; 283: 1175-82.
45. Corbett EL, Steketee RW, ter Kuile PO, Latif AS, Kamali A, Hayes RJ. HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet 2002; 359: 2177-87.
46. Clerici M, Burro S, Lukwiya M, et al. Immune activation in Africa is environmentally driven and is associated with upregulation of CCR5. AIDS 2000; 14: 2083-92.
47. Bentwich Z, Maartens G, Torten D, Lal AA, Lal RB. Concurrent infections and HIV pathogenesis. AIDS 2000; 14: 2071-81.
48. Montano MA, Nixon CP, Ndung'u T, et al. Elevated tumor necrosis factor-α activation of human immunodeficiency virus subtype I in southern Africa is associated with an NF-kB enhancer gain-of-function. J Infect Dis 2000; 181: 76-81.
49. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003; 348: 1995-2005.
50. So LK, Lau AC, Yam LY, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003; 361: 1615-17.
51. Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361: 1319-25.
52. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1967-76
53. Blau D, Holmes K. Human Coronavirus HCoV-229E enters susceptible cells via the endocytic pathway. In: The Nidoviruses, Coronaviruses and Arteriviruses. Lavi E (ed). New York: Kluwer; 2001. p 193-97.
54. Nauwynck HJ, Duan X, Favoreel HW, Van Oostveldt P, Pensaert MB. Entry of porcine reproductive and respiratory syndrome virus into porcine alveolar macrophages via receptor-mediated endocytosis. J Gen Virol 1999; 80 (Pt 2): 297-305.
55. Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361: 1767-72.
56. Shanley TP, Warner RL, Ward PA. The role of cytokines and adhesion molecules in the development of inflammatory injury. Mol Med Today 1995; 1: 40-45.
57. Nicholls JM, Poon LL, Lee KC, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003; 361: 1773-78.
58. Van Reeth K, Van Gucht S, Pensaert M. In vivo studies on cytokine involvement during acute viral respiratory disease of swine: troublesome but rewarding. Vet Immunol Immunopathol 2002; 87: 161-68.
59. Fenollar F, Fournier PE, Carrieri MP, Habib G, Messana T, Raoult D. Risks factors and prevention of Q rever endocarditis. Clin Infect Dis 2001; 33: 312-16.
60. Ladner J, Leroy V, Karita E, van de Perre P, Dabis F. Malaria, HIV and pregnancy. AIDS 2003; 17: 275-56.
61. Savarino A, Bottarel F, Malavasi F, Dianzani U. Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions? AIDS 2000; 14: 1079-89.